Ultra-low-dose naloxone or naltrexone to improve opioid analgesia: The history, the mystery and a novel approach

Clinical Medicine Insights: Therapeutics

Volumn 2, Issue , 2010, Pages 857-868

  Burns, Lindsay H ^a   Wang, Hoau Yan ^b  

^a Pain Therapeutics Inc   (United States)

^b CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

Author keywords

Anti inflammatory; Conditioned place preference; Filamin A; Naloxone; Naltrexone; Signaling

Indexed keywords

FILAMIN A; GUANINE NUCLEOTIDE BINDING PROTEIN; MORPHINE; NALMEFENE; NALOXONE; NALTREXONE; OPIATE AGONIST; OXYCODONE; OXYTREX; PLACEBO; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; BINDING AFFINITY; BINDING SITE; COMBINATION CHEMOTHERAPY; COMPETITIVE INHIBITION; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; IC 50; LOW DRUG DOSE; NONHUMAN; REVIEW;

EID: 78650719875     PISSN: 1179559X     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/CMT.S4870     Document Type: Review

References (55)

1. Shen KF, Crain SM. Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture. Brain Research. 1989; 491:227-242.
2. Crain SM, Shen K-F. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol Sci. 1990;11:77-81.
3. Crain SM, Shen K-F. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci U S A. 1995;92:10540-10544.
4. Powell KJ, Abul-Husn NS, Jhamandas A, Olmstead MC, Beninger RJ, Jhamandas K. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther. 2002;300:588-596.
5. Wang H-Y, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in Muopioid receptor-G protein coupling and Gβγ signaling. Neuroscience. 2005;135:247-261.
6. Mannelli P, Gottheil E, Peoples JF, Oropeza VC, van Bockstaele EJ. Chronic very low dose naltrexone attenuates opioid withdrawal expression. Biol Psychiatry. 2004;56:261-268.
7. Oxbro K, Trang T, Sutak M, Jhamandas KH. The effects of spinal ultra-low doses of an opioid receptor antagonist on systemic morphine dependence. Paper presented at: Society for Neuroscience, 2003.
8. Shen KF, Crain SM. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res. 1997 May 23;757(2):176-190.
9. Shen K-F, Crain SM, Moate P, Boston R, de Kater AW, Schoenhard GL. PTI-801, a novel formulation of oxycodone, shows absence of tolerance, physical dependence and naloxone-precipitated withdrawal effects in mice. J Pain. 2002;3:49.
10. Shen K-F, Crain SM, Moate P, Boston R, de Kater AW, Schoenhard GL. PTI-555, reverses and prevents morphine-induced tolerance and naloxone-precipitated withdrawal in mice chronically treated with morphine. J Pain. 2002;3:50.
11. Crain SM, Shen K-F. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res. 2001;888:75-82.
12. Olmstead MC, Burns LH. Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology. 2005;181:576-581.
13. Leri F, Burns LH. Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats. Pharmacol Biochem Behav. 2005;82:252-262.
14. Gan TJ, Ginsberg B, Glass PSA, Fortney J, Jhaveri R, Perno R. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology. 1997;87:1075-1081.
15. Cruciani RA, Lussier D, Miller-Saultz D, Arbuck DM. Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J Pain Symptom Management. 2003;25:491-494.
16. Cepeda MS, Africano JM, Manrique AM, Fragoso W, Carr DB. The combination of low dose naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period. Pain. 2002;96:73-79.
17. Cepeda MS, Alvarez H, Morales O, Carr DB. Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain. 2004; 107:41-46.
18. Joshi GP, Duffy L, Chehade J, Wesevich J, Gajraj N, Johnson ER. Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. Anesthesiology. 1999;90:1007-1011.
19. Chindalore VL, Craven RA, Butera PG, Yu KP, Burns LH, Friedmann N. Adding ultra-low-dose naltrexone to oxycodone enhances and prolongs analgesia. J Pain. 2005;6:392-399.
20. Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N. Oxytrex minimizes physical dependence while providing effective analgesia: A randomized controlled trial in low-back pain. J Pain. 2006;7(12):937-946.
21. Hamman S, Sloan P, Witt W. Low-dose intrathecal naloxone to enhance intrath-ecal morphine analgesia: a case report. J Opioid Manag. 2008;4: 251-254.
22. Imasogie N, Singh S, Watson J, Hurley D, Morley-Forster P. Ultra low-dose naloxone and tramadol/acetaminophen in elderly patients undergoing joint replacement surgery: a pilot study. Pain Res Manag. 2009;14:103-108.
23. La Vincente S, White J, Somogyi A, Bochner F, Chapleo C. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. Clin Pharmacol Ther. 2008:144-152.
24. Tompkins D, Lanier R, Harrison J, Strain E, Bigelow G. Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. Physchopharmacology. 2010;210:471-480.
25. Kest B, Sarton E, Dahan A. Gender differences in opioid-mediated analgesia. Anesthesiology. 2000;93:539-547.
26. Terner JM, Barrett AC, Lomas LM, Negus SS, Picker MJ. Infuence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains. Pain. 2006;122:90-101.
27. Crain SM, Shen K-F. Enhanced analgesic potency and reduced tolerance of morphine in 129/SvEv mice: evidence for a defciency in GM1 ganglioside-regulated excitatory opioid receptor functions. Brain Res. 2000;856:227-235.
28. Hamman SR, Malik H, Sloan JW, Wala EP. Interactions of "ultra-low" doses of naltrexone and morphine in mature and young male and female rats. Recept Chan. 2004;10:73-81.
29. Largent-Milnes TM, Guo W, Wang H-Y, Burns LH, Vanderah T. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associatedi opioid receptor-Gs coupling. J Pain. 2008;9:700-713.
30. Crain SM, Shen K-F. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/ dependence liability. Pain. 2000;84:121-131.
31. Chakrabarti S, Regec A, Gintzler AR. Biochemical demonstration of mu-opioid receptor association with Gsa: Enhancement following morphine exposure. Mol Brain Res. 2005;135:217-224.
32. Laugwitz KL, Offermanns S, Spicher K, Schultz G. Mu and delta opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma SH-SY5Y cells. Neuron. 1993;10:233-242.
33. Wang H-Y, Burns LH. GPythat interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein. J Neurbiol. 2006;66:1302-1310.
34. Gintzler AR, Chakrabarti S. Opioid tolerance and the emergence of new opioid receptor-coupled signaling. Mol Neurobiol. 2001;21:21-33.
35. Wang H-Y, Frankfurt M, Burns LH. High-affinity naloxone binding to flamin A prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence. PLoS One. 2008;3(2):1554.
36. Feng Y, Walsh C. The many faces of filamin: A versatile molecular scaffold for cell motility and signalling. Nat Cell Biol. 2004;6:1034-1038.
37. Stossel T, Condeelis J, Cooley L, et al. Filamins as integrators of cell mechanics and signalling. Nature. 2001;2:138-145.
38. Onoprishvili I, Andria M, Kramer H, Ancevska-Taneva N, Hiller J, Simon E. Interaction between the I opioid receptor and fiamin A is involved in receptor regulation and traffcking. Mol Pharmacol. 2003;64:1092-1100.
39. Liu B, Du L, Hong J-S. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglial activation and superoxide generation. J Pharmacol Exp Ther. 2000;293:517-607.
40. Qin L, Block M, Liu Y, et al. Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB. 2005; 19:550-557.
41. Hutchinson M, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone. Eur J Neurosci. 2008;28:20-29.
42. Hutchinson M, Zhang Y, Shridhar M, Evans J, Buchanan M, Zhao T. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010;24:83-95.
43. Hutchinson M, Bland S, Johnson K, Rice K, Maier S, Watkins LR. Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence and reward. Scientifc World Journal. 2007;7:98-111.
44. Mattioli T, Milne B, Cahill C. Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats. Mol Pain. 2010;6:22.
45. Lin S, Tsai R, Shen C, et al. Co-administration of ultra-low dose naloxone attenuates morphine tolerance in rats via attenuation of NMDA receptor neurotransmission and suppression of neuroinfammation in the simal cords. Pharmacol Biochem Behav. 2010;96:236-245.
46. Wang H-Y, Burns L. Naloxone's pentapeptide binding site on filamin A blocks mu opioid receptor-Gs coupling and CREB activation of acute morphine. PLoS ONE. 2009;4:4282.
47. Carlezon W, Duman R, Nestler EJ. The many faces of CREB. Trends Neurosci. 2005;28:436-445.
48. Guitart X, Thompson M, Mirante C, Greenberg M, Nestler EJ. Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine. J Neurochem. 1992;58:1168-1171.
49. Nestler EJ. Molecular neurobiology of addiction. Am J Addict. 2001;10: 201-217.
50. Nestler EJ. Molecular mechanisms of drug addiction. Neuropharmacology. 2004;47:24-32.
51. Shaw-Lutchman T, Barrot M, Wallace T, et al. Regional and cellular mapping of cAMP response element-mediated transcription during naltrex-one-precipitated morphine withdrawal. J Neurosci. 2002;22:3663-3672.
52. Marsch L, Bickel W, Badger G, et al. Effects of Infusion Rate of Intravenously Administered Morphine on Physiological, Psychomotor, and Self-Reported Measures in Humans. J Pharmacol Exp Ther. 2001;299:1056-1065.
53. Jasinski D, Pevnick J, Griffth J. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Intern Psychiat. 1978;35:501-516.
54. Zacny J, Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharm. 2003;170:242-254.
55. Burns LH, Wang HY. PTI-609: A novel analgesic that binds filamin A to control opioid signaling. Recent Patents on CNS Drug Discovery. 2010;5: 210-220.